PhaseBio plans $43M stock sale
April 12, 2019 at 11:20 AM EDT
The proceeds will be used by the Malvern biopharmaceutical company to advance both its lead new drug candidates.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.